Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
73 hedge funds and large institutions have $141M invested in Marinus Pharmaceuticals, Inc in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 25 closing their positions.
12% less funds holding
Funds holding: 83 → 73 (-10)
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
36% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 25
50% less capital invested
Capital invested by funds: $280M → $141M (-$140M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less call options, than puts
Call options by funds: $425K | Put options by funds: $876K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$4.53M |
| 2 |
Millennium Management
New York
|
+$2.34M |
| 3 |
AC
Antara Capital
New York
|
+$1.69M |
| 4 |
E
Ergoteles
New York
|
+$1.19M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$10.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.23M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.88M |
| 4 |
JP Morgan Chase
New York
|
-$1.77M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.59M |
MRNS Hedge Fund Activity: Q2 2022 in Review
73 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2022, worth a combined $141M — down 50% from $280M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MRNS and 16 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 16 added.
The largest buyer was Suvretta Capital Management, adding an estimated $4.53M. The largest seller was BlackRock, cutting an estimated $10.2M.
- 73 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2022, down from 83 in Q1 2022.
- Funds reported $141M of Marinus Pharmaceuticals, Inc stock for Q2 2022, down 50% quarter-over-quarter.
- 16 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2022 and 25 closed out, a net change of -9 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q2 2022 was Suvretta Capital Management, an estimated $4.53M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q2 2022 was BlackRock, an estimated $10.2M sold.
Based on aggregated 13F filings for Q2 2022.